3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation

• Egile Nagusiak: Yan-Rou Tsai (Egilea), Dong Seok Kim (Egilea), Shih-Chang Hsueh (Egilea), Kai-Yun Chen (Egilea), John Chung-Che Wu (Egilea), Jia-Yi Wang (Egilea), Yi-Syue Tsou (Egilea), Inho Hwang (Egilea), Yukyung Kim (Egilea), Dayeon Gil (Egilea), Eui Jung Jo (Egilea), Baek-Soo Han (Egilea), David Tweedie (Egilea), Daniela Lecca (Egilea), Michael T. Scerba (Egilea), Warren R. Selman (Egilea), Barry J. Hoffer (Egilea), Nigel H. Greig (Egilea), Yung-Hsiao Chiang (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

(<b>1</b>) <b>Background:</b> An important concomitant of stroke is neuroinflammation. Pomalidomide, a clinically available immunomodulatory imide drug (IMiD) used in cancer therapy, lowers TNF-α generation and thus has potent anti-inflammatory actions. Well-tolerated analogs...